Which has preferable earnings & valuation, MDXG or NVCR?

MiMedx Group has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $389.42M 1.41 $48.58M $0.20 18.40 NovoCure $674.41M 2.93 -$136.23M -$1.53 N/A

Is MDXG or NVCR more profitable?

MiMedx Group has a net margin of 7.88% compared to NovoCure's net margin of -25.66%. MiMedx Group's return on equity of 21.03% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 7.88% 21.03% 15.92% NovoCure -25.66% -50.82% -16.48%

Which has higher valuation and earnings, ENOV or MDXG?

MiMedx Group has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $2.25B 0.58 -$1.18B -$19.88 N/A MiMedx Group $389.42M 1.41 $48.58M $0.20 18.40

Is ENOV or MDXG more profitable?

MiMedx Group has a net margin of 7.88% compared to Enovis' net margin of -49.92%. MiMedx Group's return on equity of 21.03% beat Enovis' return on equity. Company Net Margins Return on Equity Return on Assets Enovis -49.92% 10.32% 4.57% MiMedx Group 7.88% 21.03% 15.92%

MiMedx Group (MDXG) Competitors

$3.68 +0.01 (+0.27%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$3.71 +0.03 (+0.82%)

As of 05/29/2026 07:50 PM Eastern

Compare

MDXG vs. NVCR, PLSE, PRCT, ENOV, and EYE

Should you buy MiMedx Group stock or one of its competitors? MarketBeat compares MiMedx Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MiMedx Group include NovoCure (NVCR), Pulse Biosciences (PLSE), PROCEPT BioRobotics (PRCT), Enovis (ENOV), and National Vision (EYE). These companies are all part of the "medical equipment" industry.

How does MiMedx Group compare to NovoCure?

MiMedx Group (NASDAQ:MDXG) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

MiMedx Group has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$389.42M	1.41	$48.58M	$0.20	18.40
NovoCure	$674.41M	2.93	-$136.23M	-$1.53	N/A

MiMedx Group has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, NovoCure has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

MiMedx Group has a net margin of 7.88% compared to NovoCure's net margin of -25.66%. MiMedx Group's return on equity of 21.03% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
NovoCure	-25.66%	-50.82%	-16.48%

MiMedx Group currently has a consensus target price of $8.50, indicating a potential upside of 130.98%. NovoCure has a consensus target price of $27.29, indicating a potential upside of 60.13%. Given MiMedx Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe MiMedx Group is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, NovoCure had 1 more articles in the media than MiMedx Group. MarketBeat recorded 2 mentions for NovoCure and 1 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.87 equaled NovoCure'saverage media sentiment score.

Company	Overall Sentiment
MiMedx Group	Very Positive
NovoCure	Very Positive

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Comparatively, 5.5% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

MiMedx Group beats NovoCure on 10 of the 15 factors compared between the two stocks.

How does MiMedx Group compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Pulse Biosciences has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MiMedx Group has a net margin of 7.88% compared to Pulse Biosciences' net margin of 0.00%. MiMedx Group's return on equity of 21.03% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
MiMedx Group	7.88%	21.03%	15.92%

Pulse Biosciences presently has a consensus price target of $30.00, indicating a potential upside of 20.00%. MiMedx Group has a consensus price target of $8.50, indicating a potential upside of 130.98%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts plainly believe MiMedx Group is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	4,943.57	-$72.78M	-$1.10	N/A
MiMedx Group	$389.42M	1.41	$48.58M	$0.20	18.40

In the previous week, Pulse Biosciences had 1 more articles in the media than MiMedx Group. MarketBeat recorded 2 mentions for Pulse Biosciences and 1 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.87 beat Pulse Biosciences' score of 0.96 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulse Biosciences	Positive
MiMedx Group	Very Positive

Summary

MiMedx Group beats Pulse Biosciences on 12 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to PROCEPT BioRobotics?

PROCEPT BioRobotics (NASDAQ:PRCT) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 6.6% of PROCEPT BioRobotics shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PROCEPT BioRobotics currently has a consensus price target of $41.45, indicating a potential upside of 57.44%. MiMedx Group has a consensus price target of $8.50, indicating a potential upside of 130.98%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

PROCEPT BioRobotics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

MiMedx Group has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	4.87	-$95.57M	-$1.82	N/A
MiMedx Group	$389.42M	1.41	$48.58M	$0.20	18.40

MiMedx Group has a net margin of 7.88% compared to PROCEPT BioRobotics' net margin of -31.82%. MiMedx Group's return on equity of 21.03% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
MiMedx Group	7.88%	21.03%	15.92%

In the previous week, PROCEPT BioRobotics had 3 more articles in the media than MiMedx Group. MarketBeat recorded 4 mentions for PROCEPT BioRobotics and 1 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.87 beat PROCEPT BioRobotics' score of 0.98 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Overall Sentiment
PROCEPT BioRobotics	Positive
MiMedx Group	Very Positive

Summary

MiMedx Group beats PROCEPT BioRobotics on 11 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Enovis?

Enovis (NYSE:ENOV) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

MiMedx Group has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.58	-$1.18B	-$19.88	N/A
MiMedx Group	$389.42M	1.41	$48.58M	$0.20	18.40

MiMedx Group has a net margin of 7.88% compared to Enovis' net margin of -49.92%. MiMedx Group's return on equity of 21.03% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
MiMedx Group	7.88%	21.03%	15.92%

Enovis has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

In the previous week, MiMedx Group had 1 more articles in the media than Enovis. MarketBeat recorded 1 mentions for MiMedx Group and 0 mentions for Enovis. MiMedx Group's average media sentiment score of 1.87 beat Enovis' score of 0.00 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Enovis	Neutral
MiMedx Group	Very Positive

Enovis currently has a consensus target price of $44.50, suggesting a potential upside of 96.60%. MiMedx Group has a consensus target price of $8.50, suggesting a potential upside of 130.98%. Given MiMedx Group's higher probable upside, analysts plainly believe MiMedx Group is more favorable than Enovis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

98.5% of Enovis shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Comparatively, 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

MiMedx Group beats Enovis on 11 of the 17 factors compared between the two stocks.

How does MiMedx Group compare to National Vision?

MiMedx Group (NASDAQ:MDXG) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

79.2% of MiMedx Group shares are held by institutional investors. 2.5% of MiMedx Group shares are held by company insiders. Comparatively, 2.4% of National Vision shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MiMedx Group has a net margin of 7.88% compared to National Vision's net margin of 2.31%. MiMedx Group's return on equity of 21.03% beat National Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
National Vision	2.31%	6.41%	2.81%

In the previous week, National Vision had 3 more articles in the media than MiMedx Group. MarketBeat recorded 4 mentions for National Vision and 1 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.87 beat National Vision's score of 1.66 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Overall Sentiment
MiMedx Group	Very Positive
National Vision	Very Positive

MiMedx Group has higher earnings, but lower revenue than National Vision. MiMedx Group is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$389.42M	1.41	$48.58M	$0.20	18.40
National Vision	$2.02B	0.66	$29.60M	$0.57	29.39

MiMedx Group currently has a consensus price target of $8.50, indicating a potential upside of 130.98%. National Vision has a consensus price target of $30.08, indicating a potential upside of 79.60%. Given MiMedx Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe MiMedx Group is more favorable than National Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

MiMedx Group has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, National Vision has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Summary

MiMedx Group beats National Vision on 11 of the 16 factors compared between the two stocks.

Get MiMedx Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXG vs. The Competition

Export

Metric	MiMedx Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$548.12M	$3.40B	$6.48B	$12.62B
Dividend Yield	N/A	2.28%	2.69%	5.24%
P/E Ratio	18.40	18.72	21.20	26.27
Price / Sales	1.41	192.70	531.61	96.46
Price / Cash	6.62	124.68	43.65	57.38
Price / Book	2.26	7.27	10.60	7.33
Net Income	$48.58M	$24.20M	$3.56B	$337.06M
7 Day Performance	1.66%	4.18%	2.81%	3.34%
1 Month Performance	9.52%	6.85%	4.57%	5.46%
1 Year Performance	-43.12%	66.32%	37.64%	39.65%

MiMedx Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXG MiMedx Group	4.0066 of 5 stars	$3.68 +0.3%	$8.50 +131.0%	-43.8%	$548.12M	$389.42M	18.40	870	Positive News High Trading Volume
NVCR NovoCure	2.8613 of 5 stars	$18.54 +3.2%	$27.29 +47.2%	-12.2%	$2.15B	$655.35M	N/A	1,605	Positive News
PLSE Pulse Biosciences	2.5919 of 5 stars	$26.08 +0.7%	$30.00 +15.0%	+40.1%	$1.80B	$350K	N/A	140
PRCT PROCEPT BioRobotics	3.3913 of 5 stars	$28.21 -2.7%	$41.45 +46.9%	-52.7%	$1.61B	$308.05M	N/A	430
ENOV Enovis	4.1366 of 5 stars	$24.52 +1.4%	$44.50 +81.5%	-29.3%	$1.41B	$2.25B	N/A	7,802

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXG) was last updated on 5/30/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Competitors

MDXG vs. NVCR, PLSE, PRCT, ENOV, and EYE

How does MiMedx Group compare to NovoCure?

Summary

How does MiMedx Group compare to Pulse Biosciences?

Summary

How does MiMedx Group compare to PROCEPT BioRobotics?

Summary

How does MiMedx Group compare to Enovis?

Summary

How does MiMedx Group compare to National Vision?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Competitors

MDXG vs. NVCR, PLSE, PRCT, ENOV, and EYE

How does MiMedx Group compare to NovoCure?

Which has preferable earnings & valuation, MDXG or NVCR?

Which has more risk & volatility, MDXG or NVCR?

Is MDXG or NVCR more profitable?

Do analysts recommend MDXG or NVCR?

Does the media prefer MDXG or NVCR?

Do institutionals & insiders have more ownership in MDXG or NVCR?

Summary

How does MiMedx Group compare to Pulse Biosciences?

Which has more risk and volatility, PLSE or MDXG?

Do insiders & institutionals have more ownership in PLSE or MDXG?

Is PLSE or MDXG more profitable?

Do analysts recommend PLSE or MDXG?

Which has stronger valuation & earnings, PLSE or MDXG?

Does the media prefer PLSE or MDXG?

Summary

How does MiMedx Group compare to PROCEPT BioRobotics?

Do insiders and institutionals believe in PRCT or MDXG?

Do analysts rate PRCT or MDXG?

Which has more volatility & risk, PRCT or MDXG?

Which has preferable valuation and earnings, PRCT or MDXG?

Is PRCT or MDXG more profitable?

Does the media refer more to PRCT or MDXG?

Summary

How does MiMedx Group compare to Enovis?

Which has higher valuation and earnings, ENOV or MDXG?

Is ENOV or MDXG more profitable?

Which has more volatility and risk, ENOV or MDXG?

Does the media prefer ENOV or MDXG?

Do analysts rate ENOV or MDXG?

Do insiders & institutionals believe in ENOV or MDXG?

Summary

How does MiMedx Group compare to National Vision?

Do institutionals and insiders believe in MDXG or EYE?

Is MDXG or EYE more profitable?

Does the media refer more to MDXG or EYE?

Which has better valuation & earnings, MDXG or EYE?

Do analysts rate MDXG or EYE?

Which has more risk & volatility, MDXG or EYE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools